Form 4: Revance Therapeutics Director Kolaja Disposes of Shares Following Merger Agreement

Director Carey O'Connor Kolaja reports the disposal of Revance Therapeutics shares following the completion of a merger with Crown Laboratories.

Summary

• Carey O'Connor Kolaja, a director of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 4, 2025, Kolaja disposed of 16,561 shares of common stock at $3.65 per share, and on February 6, 2025, disposed of 15,000 shares.
• These transactions occurred as a result of the merger agreement between Revance Therapeutics and Crown Laboratories, where Crown Laboratories acquired Revance Therapeutics for $3.65 per share.
• The merger was executed through a cash tender offer for all outstanding shares of Revance Therapeutics common stock.
• Restricted stock awards held by non-employee board members were canceled and converted into the right to receive $3.65 per share.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the document reports the completion of a merger, which typically provides shareholders with a defined exit strategy. The director's actions are in line with the merger agreement.

Future Outlook

The document does not contain forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects a consolidation trend in the pharmaceutical and biotechnology industries, where larger companies acquire smaller entities for their technologies or market presence. Crown Laboratories' acquisition of Revance Therapeutics is likely aimed at expanding its portfolio or gaining access to Revance's expertise in neuromodulators.

Stakeholder Impact

• Shareholders received $3.65 per share as part of the merger agreement.
• Non-employee board members received cash for their restricted stock awards.

Key Dates

Keywords

Form 4, Revance Therapeutics, Crown Laboratories, Merger Agreement, Share Disposal, Beneficial Ownership, Director, RVNC